Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Accumulated Expenses (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Accumulated Expenses for 13 consecutive years, with $7.7 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses fell 1.22% to $7.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.7 million through Dec 2025, down 1.22% year-over-year, with the annual reading at $7.7 million for FY2025, 1.22% down from the prior year.
  • Accumulated Expenses for Q4 2025 was $7.7 million at Niagen Bioscience, down from $8.7 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $10.5 million in Q1 2024, with the low at $5.6 million in Q2 2021.
  • Average Accumulated Expenses over 5 years is $8.0 million, with a median of $8.1 million recorded in 2023.
  • The sharpest move saw Accumulated Expenses soared 36.07% in 2023, then fell 17.66% in 2024.
  • Over 5 years, Accumulated Expenses stood at $6.5 million in 2021, then increased by 13.21% to $7.3 million in 2022, then grew by 29.39% to $9.5 million in 2023, then fell by 17.66% to $7.8 million in 2024, then fell by 1.22% to $7.7 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $7.7 million, $8.7 million, and $7.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.